The answer to the question of why some organisms can regenerate major body parts while others, such as humans, cannot may lie with the body's innate immune system, according to a new study of heart regeneration in the Mexican salamander by James Godwin, Ph.D., of the MDI Biological Laboratory. Godwin found that formation of new heart muscle tissue after a heart attack is dependent on the presence of macrophages, a type of white blood cell.
Researchers have developed a quality control method to evaluate the pharmacological activity and potential effectiveness of different preparations of the therapeutic agent methyl-β-cyclodextrin (MβCD).
Opening up a new pathway to fight cancer, researchers at the University of Pennsylvania have found a way to target an enzyme that is crucial to tumor growth while also blocking the mechanism that has made past attempts to target that enzyme resistant to treatment. Researchers were able to use this finding to develop a drug that successfully inhibits tumor growth of melanoma as well as pancreatic and colorectal cancer in mice.
Biopharmaceuticals, medium- and high-molecular weight biologically active macromolecules, are not easily absorbed by the small intestine, the main organ responsible for gastrointestinal absorption, resulting in a bottleneck for oral administration type biopharmaceutical development. Now, researchers have found a new small intestine permeable peptide that can facilitate digestive tract absorption of biopharmaceutical products. The discovery should make it possible for oral administration of drugs that were previously only available by injection.
An investigational therapy using modified poliovirus to attack cancer tumors appears to unleash the body's own capacity to fight malignancies by activating an inflammation process that counter's the ability of cancer cells to evade the immune system.
A new study from the University of North Carolina at Chapel Hill finds beta blockers are not needed after a heart attack if heart-attack survivors are taking ACE inhibitors and statins. The study is the first to challenge the current clinical guideline that heart-attack survivors should take all three drugs -- beta blockers, ACE inhibitors and statins -- for the rest of their lives.
Researchers at Houston Methodist have solved a 100-year-old mystery, providing them a possible key to unlock a pathway for treating diseases caused by flesh-eating bacteria. Muthiah Kumaraswami and his team at Houston Methodist Research Institute found a critical target on which to focus for developing a potential Group A Streptococcus vaccine or antibiotic to fight it. By manipulating this target, they hope to either reduce the severity of these infections or clear them up faster.
MIT engineers have developed a new 3-D fabrication method that can create a new type of drug-carrying particle that could allow several doses of a drug or vaccine to be delivered over an extended time period with just one injection.
The Journal of Nuclear Medicine's September supplement shines a spotlight on theranostics and its increasingly important role in delivering precision medicine. Theranostics refers to the combination of a predictive biomarker, identified through diagnostic imaging using radiolabeled ligands (which lock onto the specific cancer cell receptor/biomarker), with precise therapy targeted on the now-marked cancer cells. The cancer cells are destroyed, while healthy cells are unharmed -- minimizing side effects and improving quality of life for patients.
A UK charity backs a pioneering new project to prevent childhood deafness following treatment with life-saving cancer drugs.